编辑丨王多鱼 排版丨水成文 长期以来， 运动 被认为是一种典型的个体行为 —— 它可以增强体能、改善代谢状态、预防慢性疾病，但 其影响也被普遍认为止步于个体本身。然而，越来越多的证据表明，父母的生活方式，尤其是运动习惯， 可能会以 " 非 DNA " 的方式影响下一代的健康特征。这意味着，运动的益处不仅属于自己，也可能 " 写 入 " 后代的生命脚本之中。 在人类进化的漫长历程中，卓越的耐力和高效的能量利用能力曾是生存的关键；而在现代社会，久坐与缺 乏运动却成为常态。尽管运动被广泛认为有益于个体代谢健康，但运动如何将这些有益效应 进行 " 跨代传 递 " ，其分子基础一直是运动生物学与表观遗传学交叉研究的前沿难题。传统遗传学观点认为，遗传信息 的传递完全依赖 DNA 序列。然而，近年来的研究发现， 精子中存在大量功能性的小 RNA 分子 ，尤其是 microRNA （miRNA） ，它们在受精后能够参与早期胚胎的基因调控过程。这一发现为 " 生活方式可以遗 传 " 的假说提供了新的可能。 2025 年 10 月 6 日，南京大学 张辰宇 、 陈熹 、 陈迪俊 团队联合南京医科大学 张涛 ，在 Cell 子刊 ...

1940-1970年代，中国表观遗传学处于探索奠基阶段。1942年，英国生物学家Conrad Waddington首次提 出"表观遗传学"概念，但中国受苏联李森科主义影响，遗传学发展受阻。1950年代，摩尔根学派被压 制，表观遗传学研究停滞。1952年高校院系调整削弱了清华大学、浙江大学等高校的遗传学专业。1956 年"青岛会议"后遗传学短暂发展，但"文化大革命"期间研究再次受冲击。1978年中国遗传学会成立，遗 传学研究恢复发展，为表观遗传学奠定基础。 1980-1990年代，中国表观遗传学进入初步发展阶段。改革开放后，中国引进国际先进遗传学理论，表 观遗传学逐渐被引入。1980年代，DNA甲基化、组蛋白修饰等机制开始被研究。1990年代，中国科学 家参与国际研究，如1996年C. David Allis发现组蛋白乙酰转移酶。1990年代，中国启动"863计划""973 计划"等，支持遗传学与表观遗传学研究。 内容概况：近年来，中国表观遗传学行业取得了显著进展，逐渐成为生命科学领域的研究热点。2024 年，中国表观遗传学行业市场规模约为43.96亿元，同比增长62.27%。这不仅反映了技术的不断进步， 也体 ...

使用对乙酰氨基酚治疗的疾病本身的风险更大，可能给孕妇和胎儿带来严重的发病率和死亡率。 美国总统特朗普近日将美国自闭症诊断数量的上升与孕妇服用一种常见药"泰诺"关联。9月24日，世界 卫生组织澄清：目前尚无确凿科学证据证明自闭症与孕期服用对乙酰氨基酚（"泰诺"的主要成分）之间 存在关联。 美国妇产科医师学会也建议，孕妇可以在医生的监督下根据需要使用泰诺。该学会认为，使用对乙酰氨 基酚治疗的疾病本身的风险更大，可能给孕妇和胎儿带来严重的发病率和死亡率。 美国的自闭症诊断数量显著增加，加剧了公众对患病率上升原因的担忧。美国政府数据显示，2022年8 岁儿童的自闭症诊断数量创历史新高，每31名儿童中就有1名患有自闭症。 世界卫生组织估算，目前全球儿童自闭症患病率为1%，这一数据在十年前大约为0.6%。 全球平均诊断年龄为5岁 自闭症是一种神经系统和发育疾病，其特征是大脑信号传导中断，导致患者的行为、交流、互动和学习 方式异常。 目前尚无客观工具可以诊断自闭症谱系障碍（ASD），例如血液检查或脑部扫描，临床的诊断通常基于 观察和访谈。 "谱系"反映了自闭症谱系障碍（ASD）的广泛潜在表现。 自闭症、阿斯伯格症和广泛性发 ...

Core Concept - The article discusses the concept of the "triple helix" proposed by R.C. Lewontin, emphasizing the interaction and influence among genes, organisms, and the environment [1][8]. Group 1: Genetic Determinism Debate - Lewontin criticizes genetic determinism, arguing that the human genome differs by less than 0.1%, yet it is misused to explain social inequalities such as wealth, intelligence, and crime [5][6]. - He asserts that the environment is not merely a container but is actively shaped by organisms, which select and modify their surroundings [5][8]. - The completion of the Human Genome Project, according to Lewontin, will not achieve its intended purpose of identifying disease-causing genes through DNA comparison [5][6]. Group 2: Responses from Richard Dawkins - Richard Dawkins responds to Lewontin's critiques, clarifying that he never claimed genes determine everything, but rather that genetic differences can explain phenotypic variations [6]. - Dawkins emphasizes the directionality of evolution, countering Lewontin's and Gould's views on randomness in evolution by citing examples like the speed of cheetahs [6]. - He argues that moral responsibility should not be outsourced to science, maintaining a distinction between scientific conclusions and their political implications [6]. Group 3: Impact on Biological Sciences - The debate between Lewontin and Dawkins has had a lasting impact on the field of biology, with new perspectives emerging, such as those presented by behavior geneticist Kathryn Harden in her book "The Gene Lottery" [7]. - Harden attempts to find a middle ground, acknowledging the significant role of genes while also recognizing the influence of luck and the potential for social policies to mitigate genetic impacts [7]. - However, Lewontin remains critical of this middle ground, insisting that the interactions among genes, environment, and randomness are too complex to disentangle [7][8]. Group 4: Science as a Social Institution - Lewontin argues that science is not an isolated pursuit of truth but a social institution influenced by political and economic factors [10][11]. - The direction of scientific research is often driven by societal needs and interests, rather than purely by the quest for knowledge [10][12]. - Cultural and ideological contexts shape scientific inquiry, affecting research focus and methodologies across different societies [11][12]. Group 5: Historical Context and Future Implications - Historical examples illustrate the close relationship between biology and political ideologies, such as the use of Darwinian theory in imperialism and eugenics [12]. - The ongoing developments in biological sciences, particularly in the context of the COVID-19 pandemic, raise questions about the political implications of scientific advancements [12].

Core Viewpoint - The global beauty industry is facing growth bottlenecks, and Beiersdorf is not immune to this trend, as indicated by its recent financial report for the first half of 2025, which reveals performance slowdowns, profit pressures, and brand performance disparities [2][4]. Financial Performance - Beiersdorf reported revenue of €5.188 billion (approximately ¥434.45 billion), a year-on-year increase of 0.2% (organic growth of 2.1%), which is a significant slowdown compared to last year's 4.3% (organic growth of 7.1%) [8]. - The consumer goods segment, which accounts for over 80% of total revenue, generated €4.33 billion (approximately ¥362.6 billion), remaining flat year-on-year (organic growth of 1.9%) [8]. Brand Performance - The Derma brand continues to act as a "growth engine," with strong performances from Eucerin and Aquaphor driving a growth of 10.5% (organic growth of 12.2%) [10]. - Conversely, the luxury skincare brand La Prairie saw a decline of 10.8% (organic decline of 10.7%), despite achieving 3% growth in China during Q2, reflecting the broader trend of low demand in the global high-end market [10]. - Nivea, the largest brand in the consumer segment, experienced a decline of 1.2% (organic growth of 1.0%), indicating a critical period of brand adjustment [10]. Strategic Adjustments - Beiersdorf has lowered its full-year guidance for 2025, adjusting the organic sales growth target from 4-6% to approximately 3%, and the EBIT margin expectation from a 50 basis point increase to a 20 basis point increase [12]. - The company is focusing on innovation to drive growth, with plans for a significant new product launch from Nivea, the "Epigenetic Essence," set to launch in September across 30 countries [19][20]. Market Dynamics in China - In China, Beiersdorf has shown significant structural adjustments and channel breakthroughs, with La Prairie achieving 3% organic growth, primarily driven by a 36% surge in e-commerce sales [15][26]. - Nivea is undergoing structural adjustments, particularly in lower-tier cities, where it is shifting from low-margin products to higher-end offerings, aiming to better align with consumer preferences [17]. - The upcoming launch of Nivea's epigenetic essence is expected to be the largest product launch in the company's history, with a price point 40-50% lower than Eucerin, aiming to capture a larger consumer base [19][20]. Future Outlook - Beiersdorf's growth in China will depend on its ability to penetrate core segments and compete effectively against rivals in terms of efficiency and content [22]. - The company is strategically focusing on the skincare segment, reducing low-margin SKUs, and introducing innovative products to attract a broader consumer base [22][24]. - The successful performance of Eucerin and the recovery of La Prairie in the e-commerce space are seen as positive indicators for future growth [20][26].

Core Viewpoint - The Chinese Academy of Sciences' Institute of Biophysics plans to invest a total of 83.01 million yuan in the construction of three national key laboratories focusing on epigenetic regulation, biomolecules, and cognitive science and mental health [2][10]. Group 1: Epigenetic Regulation and Intervention National Key Laboratory - The Epigenetic Regulation and Intervention National Key Laboratory was approved on January 18, 2023, and aims to address major scientific issues in epigenetics, particularly related to significant diseases and aging [3]. - The laboratory's mission includes gathering influential talent to lead the international forefront of epigenetics and fill gaps in the national innovation system [3]. - Key research directions include chromatin structure and epigenetic regulation mechanisms, phylogenetic and homeostatic epigenetic mechanisms, and chromatin regulation related to aging and disease [6]. Group 2: Biomolecule National Key Laboratory - The Biomolecule National Key Laboratory, established in 1989, has consistently received excellent evaluations and focuses on proposing new questions and discovering new phenomena in life sciences [7]. - The laboratory aims to break through key technological bottlenecks and establish a complete research chain for drug target identification and vaccine design [7]. - Research will focus on supramolecular assembly rules, structure-based biomolecule simulation and design, and elucidating the dynamics of the endomembrane system [7]. Group 3: Cognitive Science and Mental Health National Key Laboratory - The Cognitive Science and Mental Health National Key Laboratory was restructured from the former National Key Laboratory of Brain and Cognitive Science and aims to explore cognitive neuroscience mechanisms related to mental health [9]. - The laboratory will focus on understanding the emergence of consciousness and its assessment, as well as precise adjustments for mental health [12]. - Key research directions include mechanisms of consciousness emergence, assessment of abnormal states of consciousness, and precise mental health adjustments [12].

Core Viewpoint - MD Anderson Cancer Center is recruiting postdoctoral researchers to advance cutting-edge single-cell multi-omics technologies and explore molecular regulatory networks in cancer development and drug resistance [3][8]. Group 1: Research Focus - The laboratory aims to develop single-cell multi-omics technologies, investigate the epigenetic regulatory mechanisms of cancer cell plasticity, and understand the epigenetic basis of individualized drug responses [3]. - The research group is led by Dr. Zhang Bingjie, who has a strong background in epigenomics and single-cell multi-omics [2]. Group 2: Institutional Overview - MD Anderson Cancer Center is a leading cancer treatment and research institution, consistently ranked as the top cancer specialty by U.S. News & World Report, located in Houston, Texas [8]. - The center has conducted over 1,680 clinical trials in 2024, with 22 drugs approved by the FDA and research funding amounting to $1.1 billion [8]. Group 3: Application Requirements - The position is for two postdoctoral researchers in genomics and tumor biology, requiring a Ph.D. in relevant biological fields [9][10]. - Candidates with backgrounds in tumor biology, genomics, and computational biology are preferred, along with strong communication and teamwork skills [10][11].

Financial Data and Key Metrics Changes - In 2024, the company recorded $1.2 million in revenue, a growth of 59% over 2023 [28] - Revenue from the NUQ VET cancer test was $0.8 million, growing by 75% compared to the prior year [28] - Operating expenses were reduced by 23% year-on-year, with second half operating expenses down 31% [30] - Net cash used in operating activities was $25.9 million in 2024, compared to $18.1 million in 2023 [31] Business Line Data and Key Metrics Changes - Approximately 120,000 NUQ VET cancer tests were sold in 2024, more than double the sales in 2023 [28] - Revenue from the NUQ Discover pillar was approximately $400,000, with a year-on-year growth of 40% [29] - The company recorded its first revenue from the NUQ NETS, marking a significant milestone [29] Market Data and Key Metrics Changes - The NUQ VET cancer test is now available in over 20 countries, expanding access significantly [18] - The point-of-care market is noted to be less than 20% of the total market, indicating growth potential [22] Company Strategy and Development Direction - The company aims to sign multiple licensing deals in 2025, focusing on human applications of its technology [11] - There is a strong interest in potential out-licensing and supply agreements for both NUQ NETS and the oncology portfolio [12] - The strategy includes raising non-dilutive funds, ramping revenues, reducing expenses, and signing commercial deals with large industry players [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash neutrality on a full-year basis by 2025 [27] - The company is at a pivotal juncture, ready to revolutionize diagnostics for both animals and humans [12] - Management highlighted the importance of automation in centralized labs to accelerate growth [22] Other Important Information - The company received approximately $1.8 million in non-dilutive funding from Belgian institutions during 2024 [33] - The NUQ platform has shown broad applicability across various established platforms, enhancing its market potential [14] Q&A Session Summary Question: Update on the feline cancer testing program - Management confirmed that the feline cancer testing program is on track for completion later this year, with a milestone payment of $5 million expected upon completion [80] Question: Discussion on the Leon study and its implementation - Management indicated that there are plans for prospective studies following the results of the Leon study, with potential rapid adoption in cancer programs [86][90] Question: Insights on quarterly sales trends and outlook for 2025 - Management noted that sales were lumpy due to large customers ordering in batches, but solid growth was achieved with 120,000 tests sold [100] - Automation in central labs is expected to open up larger opportunities in 2025 [101] Question: Approach to managing financing risks - Management emphasized a tight grip on expenses and cash flows while focusing on securing licensing agreements [112] Question: Activity and interest in data rooms for licensing agreements - Management reported that the data generated exceeded expectations and has been crucial in energizing discussions with major companies [118]